Subscriber Update - Nov 2022
Dear Subscriber,
Welcome to the sixth issue of Equity Midas Capital’s Subscriber Update. This letter marks the second quarterly review of the IY2022-23 (IY = Investment Year, 31 May 2022 to 31 May 2023) recommendations.
Overall, the second quarter(Sep-Nov) passed off without any major surprises. While the geo-political tensions continued, fortunately, the inflation flare-up stabilized causing the central banks to slow down on the interest rate hikes. As discussed in our earlier updates, interest rates have a crippling impact on stock valuations. Central banks need to respond to higher inflation by raising interest rates which in-turn impacts stock market returns.
With stability in interest rates, stock markets re-focus on company performance. This quarter, performance of the stocks had a very high correlation with the company operating performance. Corporate results were also in-line or slightly better than the analyst estimates. Here is a link to an external report that will give some more information: https://www.sharekhan.com/MediaGalary/newsletter/Specialreport.pdf
Stock markets are people. Human nature, hence, is the biggest driver of stock price volatility. When there are urgent matters to take care of (like macro conditions, inflation, interest rates, war, pandemic) the important aspects (long term company operating performance) take a back seat. Whether the urgent matters impact the underlying company’s business is often ignored. Long term gets muddied by short term and stock prices become volatile.
Fortunately, this quarter was a quite quarter. Hoping that the situation continues.
Stock Performance Analysis
Out-performance of Focus (large & mid cap stocks) continued over Feast (large, mid, small & micro cap stocks) this quarter. I believe that this out-performance is here to stay till the market gets convinced about future stability. As long as future looks unstable (due to war, inflation, covid), markets will prefer the stability of large and mid caps over small & micro caps.
As on end of Nov 2022, an equal-weighted portfolio of our 2022-23 FEAST recommendations (in other words the average returns for our FEAST recommendations) has yielded 16.8% capital returns i.e. without dividends. FOUCS recommendations have yielded 21.8% capital returns in this period.
Both the portfolios have performed better than their benchmark indices. The overall returns are within the expected range considering the underlying company performances.
Lets see how we got here:
Key Observations
- From the lows of the year, both feast and focus recommendations have performed good.
- Within the small & micro cap universe, the tradition of couple of stocks pulling the up the average returns continues.
- Companies that did not do well operational in Q1, failed to perform in Q2 as well.
Operating Performance Analysis - EVM View
QUADRANT | NUMBER OF COMPANIES | AVERAGE RETURNS | EXPECTATIONS ACHIEVED |
---|---|---|---|
1 | 3 | -26.91% | <=40 |
2 | 1 | -3.99% | >40 & <45 |
3 | 4 | 20.65% | >45 & < 50 |
4 | 7 | 36.34% | >50 |
Here is the detailed data of the company performance:
QUADRANT | TRANCHE | MARKET_CAP_CLASS | COMPANY | EXPECTATIONS ACHIEVED (%) | RETURNS (%) | PE RATIO | 5 YR MEDIAN PE |
---|---|---|---|---|---|---|---|
1 | May | SMALL/MICRO CAP | Sharda Cropchem Ltd. | 15.11 | -42.6 | 11.9 | 21.1 |
1 | June | SMALL/MICRO CAP | Gujarat Ambuja Exports Ltd. | 25.85 | -32.01 | 12.0 | 27.9 |
1 | July | SMALL/MICRO CAP | Transport Corporation Of India Ltd. | 27.2 | -6.13 | 16.9 | 9.6 |
2 | August | LARGE/MID CAP | SRF Ltd. | 44.6 | -3.99 | 31.9 | 17.1 |
3 | September | LARGE/MID CAP | Timken India Ltd. | 45.47 | 44.99 | 61.1 | 8.7 |
3 | October | LARGE/MID CAP | Sun Pharmaceutical Industries Ltd. | 46.17 | 21.55 | 61.2 | 24.0 |
3 | November | LARGE/MID CAP | Cipla Ltd. | 47.53 | 14.77 | 35.9 | 6.5 |
3 | December | LARGE/MID CAP | UPL Ltd. | 48.88 | 1.3 | 14.8 | 8.7 |
4 | January | SMALL/MICRO CAP | Fineotex Chemical Ltd. | 51.87 | 76.5 | 47.2 | 15.9 |
4 | February | LARGE/MID CAP | ITC Ltd. | 56.41 | 25.62 | 24.4 | 39.0 |
4 | March | SMALL/MICRO CAP | Apcotex Industries Ltd. | 57.01 | -19.82 | 21.3 | 21.9 |
4 | April | SMALL/MICRO CAP | Kama Holdings Ltd. | 57.7 | 15.5 | 7.0 | 43.1 |
4 | May | LARGE/MID CAP | Solar Industries India Ltd. | 60.66 | 48 | 56.9 | 45.1 |
4 | June | SMALL/MICRO CAP | Nitta Gelatin India Ltd. | 62.57 | 100.16 | 12.0 | 16.0 |
4 | July | SMALL/MICRO CAP | E.I.D. – Parry (India) Ltd. | 65.33 | 8.41 | 10.2 | 17.1 |
Investor Queries
Q1. A few stocks from your previous year recommendations like Permanent Magnets and Refex are doing very well. Why did you recommend a SELL in such stocks?
Ans: This is something that every investor dreads of. What if the stock goes up after we sell? If we review our previous year portfolio, some stocks that we sold are doing very well.
A simple answer to the question is that both those stocks were not filtered by the model this year. We do not study individual companies using fundamental or technical analysis. The quantitative model looks at companies like a black box, a financial black box and relies on how the market values the company rather than doing any kind of valuation excercise.
We recommend a holding period of one year and as re BUY recommendations are identified, we recommend a SELL on all previous year holdings. All stocks bought previous year are recommended a SELL by on the day we recommend BUY of our next years stocks. Some stocks so reappear (like SRF this year), but that is only because the quantitative model filtered it for this year. The entire portfolio is re-balanced every year.
As on Nov 30, if we would have held on to the entire 2021-22 portfolio, the incremental returns (from May 31, 2021) would have been close to 7%. The 2022-23 portfolio in the same time frame, has delivered close to 22% returns (including dividends). The point is that the re-balancing process is very important to ensure that we are invested in the group of stocks every year.
Q2. There is a buy-back announced by Kama Holdings, should we participate? Similarly there is rights issue planned for Nitta Gelatin, do we participate in that?
Ans: None of these corporate actions have been tested by us when we tested the model. So by default, we recommend not participating in buy-backs.
Rights issue is a different ball-game. Last year, GPIL declared a rights issue at 10Rs when the stock was priced at above 2000Rs in the market. In such situations we have not option but to participate in the rights issue. If we do not, the market value of our holdings (of GPIL) would have declined by 2/3rd. The cost out-go of participation would have have any impact on the overall capital allocation either. Such situations are rare but vital.
Rest assured, if such corporate actions have a direct impact on our portfolio returns, we will provide you with the possible scenarios and our recommendations.
Current Affairs
We redesigned the website this quarter. Websites performance was not up to the mark and its design was bulky. We did try a set of new designed but reverted back to the original concept since we felt it was the right way to share the quantitative concepts and the EVM model details with the reader.
We also had to more or less rewrite the entire code to match the new data source. This also allows us to retest our model and catch any bugs. Thus far, nothing new and the test results match our prior testing. This effort is expected to continue in the next quarter as well.
The demand driven model is going well, but no concrete progress worth reporting.
SEBI Registered Research Analyst
Equity Midas Capital
equitymidas.com